Kovo HealthTech Announces Departure of Greg Noble as CEO and Appointment of Brenner Adams as Interim Successor
Kovo HealthTech Announces Departure of Greg Noble as CEO and Appointment of Brenner Adams as Interim Successor
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company") today announced that Mr. Greg Noble has stepped down as Chief Executive Officer and that the Board of Directors has selected Brenner Adams to succeed Mr. Noble as interim CEO.
加拿大卑诗省--(新闻稿-2024年7月9日)-Kovo卫生科技有限公司(TSXV: KOVO) ("Kovo" or the "公司")今日宣布,Greg Noble先生已经辞去首席执行官职务,董事会选择Brenner Adams接替Noble担任临时首席执行官。
During his tenure, Mr. Noble led the Company's public listing on the TSX Venture Exchange and oversaw several acquisitions and operational efficiencies that grew the company from $1.7M to $10.0M from Fiscal 2019 to Fiscal 2023. Whereas Mr. Noble is departing as CEO, he has signed a long-term contract to provide M&A consulting services for the Company. "KOVO is now well positioned as an acquisition engine for continued growth into the future and I look forward to assisting the team in finding new and valuable RCM targets to purchase," stated Noble.
Noble先生任CEO期间,领导了公司在TSX创业板上市,并监督了多项收购和运营效率,使公司从2019财年的170万美元增长到2023财年的1000万美元。虽然Noble先生即将离任CEO,但他已签订一份长期合同,为公司提供并购咨询服务。「KOVO现在已经做好了成为未来持续增长的收购引擎的准备,我期待协助团队寻找新的有价值的RCm目标进行收购。」Noble表示。
Stepping into the CEO position, Brenner Adams is an international executive with a robust background in business development, marketing, and product leadership who significantly impacted the healthcare industry during his tenure as Chief Innovation Officer at Med USA, a Revenue Cycle Management and Credentialing Services company. Additionally, Adams helped launch two successful spinoffs, with one securing public state funding in the process. The Board believes Adams is well-equipped to ensure a seamless transition and continue the company's aggressive growth trajectory.
Brenner Adams担任CEO一职,是一位具有丰富的商业拓展、市场营销和产品领导经验的国际高管,曾在医疗行业担任过收入循环管理和资格认证服务公司Med USA的首席创新官,产生了重大影响。此外,Adams还帮助推出了两个成功的子公司,其中一个子公司在过程中获得了公共国家资金的支持。董事会认为Adams已经准备好确保无缝过渡,并继续公司的强劲增长轨迹。
"We extend our gratitude to Greg for his leadership and unwavering dedication during his tenure as CEO and we are confident in Brenner's ability to continue the Company's growth and excellence in all aspects during this transitional period and beyond," said Peter Bak, Kovo's Chairman of the Board.
Kovo董事长Peter Bak表示:"我们感谢Greg在他担任CEO期间的领导和坚定的奉献精神,并且我们对Brenner在这个过渡期间和未来所有方面继续推动公司的增长与卓越能力充满信心。"
About Kovo HealthTech Corporation
Kovo HealthTech Corporation简介
Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .
Kovo HealthTech Corporatio是一家快速增长的医疗技术公司,专门提供SaaS样式的医疗账单管理服务,为2250多家美国医疗机构提供软件服务。Kovo帮助医疗服务提供商以无缝的方式处理和管理繁琐的患者护理登记、服务、账单和支付。目前,通过其客户,Kovo每年为超过350万患者处理超过2.5亿加元(2亿美元)的年度账单交易。通过提供有效的账单实践,Kovo帮助医疗从业者得到报酬,以便他们可以专注于提供优质的医疗保健服务。有关Kovo的更多信息以及Kovo新闻的最新动态,请访问 。
For more information:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777
欲了解更多信息:
Kovo董事长
为提供公司管理人员有关未来的期望和计划的信息而提供前瞻性陈述和信息。读者应该注意,依赖这种陈述和信息可能不适用于其他目的,例如做出投资决策。由于前瞻性陈述和信息涉及未来事件和条件,因其本质而言,它们涉及固有的风险和不确定性。由于多种因素和风险,实际结果可能会与当前预期有所不同。这些因素和风险包括公司在没有足够资本的情况下继续运营的能力,公司筹集进一步资金的能力,公司符合其当前债务义务并能够无论是否进行债务转换交易和贷款协议修正来偿还其债务,公司有可能满足拟议中的债务转换交易和贷款协议的继续义务,公司有效并成功地开发新机会的能力,未来交易对手的识别失败以及重组债务交易被完成的可能性以及公司未来不违约的可能性。因此,读者不应过分依赖本新闻稿中包含的前瞻性陈述和信息。读者应该注意,上述因素列表并非详尽无遗。本新闻稿中包含的前瞻性陈述和信息是截至本日的,并没有承诺公开或修正任何前瞻性陈述或信息,无论是基于新信息,未来事件还是其他原因,除非适用的证券法要求这样做。本新闻稿中包含的前瞻性陈述或信息明确受到本警示说明的限制。
1-866-558-6777
Forward-Looking Information
前瞻性信息本新闻稿包含包含“前瞻性信息”,涵盖适用证券法律的范围。在某些情况下,“前瞻性信息”可以通过使用前瞻性术语诸如“计划”、“预期”、“预算”、“安排”、“估计”、“前景”、“目标”、“预测”、“投影”、“潜力”、“前景”、“策略”、“意图”、“预计”、“寻求”、“认为”、“机会”、“指引”、“目标”或类似的词语和短语或陈述一定的未来条件、行动、事件或结果“可能”、“可能”、“将”、“应该”、“可能”、“将”、“能够”或这些词语和短语的负面版本,“被采取”,“发生”,“继续”或“实现”,以及其他类似的表达方式。包含前瞻性信息的声明并不是历史事实,而是代表管理层对于未来事件或情况的预期、估计和投射。该前瞻性信息与公司未来的财务前景以及预期的事件或结果有关,包括但不限于“财务前景”下的声明和有关公司财务状况、财务结果、业务策略、绩效、成就、前景、目标、机会、业务计划和增长策略、公司预算、运营和税务、影响财务报表的判断和估计以及D2L Wave的初步分拆。
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to future acquisitions and relative growth of the Company. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
本新闻稿包含前瞻性声明和前瞻性信息,根据适用的证券法规,它们涉及未来事件或未来表现。除历史事实陈述外,所有陈述可能均为前瞻性声明或信息。特别是,此新闻稿包含前瞻性声明和信息,涉及未来收购和公司相对增长。前瞻性声明和信息基于公司管理层做出的某些关键预期和假设。尽管公司管理层相信,前瞻性声明和信息所基于的预期和假设是合理的,但不应过分依赖前瞻性声明和信息,因为无法保证它们将被证明是正确的。
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise future capital, the Company's ability to meet the terms of its current debt obligations and to repay its indebtedness, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties . Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
本新闻稿中的前瞻性声明和信息提供有关公司管理层的当前期望和计划的信息,涉及未来。读者应该注意,依赖此类声明和信息可能不适合其他用途,例如进行投资决策。由于前瞻性声明和信息涉及未来事件和条件,因其本质具有固有的风险和不确定性,因此实际结果可能与目前预期的结果有所不同。由于许多因素和风险的影响,实际结果可能与当前预期的结果有很大差异。这些因素和风险包括但不限于:公司筹集未来资本的能力;公司能否满足其当前的债务义务并偿还其债务;公司高效、成功地开发新机会,未来交易的交易对手未被发现。因此,读者不应依赖此新闻稿中包含的前瞻性声明和信息。读者应该注意,上述因素列表并非详尽无遗。本新闻稿中包含的前瞻性声明和信息是截至本日发布,且未承诺公开更新或更正任何前瞻性声明或信息,除非适用的证券法律规定要求这样做。本新闻稿中包含的前瞻性声明或信息受到此警示声明的明确限制。